中国肛肠病杂志2025，Vol.45Issue(5)：17-20,4.
曲氟尿苷替匹嘧啶片联合贝伐珠单抗治疗晚期转移性结肠癌的临床研究
Clinical Study on Trifluridine and Tipiracil Tablets Combined with Bevacizumab in Treatment of Advanced Metastatic Colon Cancer
摘要
Abstract
Objective To explore the efficacy and safety of trifluridine and tipiracil tablets(TAS-102)combined with bevacizumab in the treatment of advanced metastatic colon cancer.Methods The data of 96 patients with advanced metastatic colon cancer who received TAS-102 for the third-line and above treat-ment in our hospital from October 2022 to September 2023 were retrospectively collected.Among them,50 patients were treated with TAS-102 alone(control group),and 46 patients were treated with TAS-102 combined with bevacizumab(observation group).The objective response rate(ORR),disease control rate(DCR),progression-free survival time(PFS),1-year survival rate,and the occurrence of toxic and side effects were compared between the two groups.Results The ORR(41.30％)and DCR(78.26％)in the observation group were higher than those in the control group(22.00％,62.00％),and the differences were statistically significant(P＜0.05).Follow-up was conducted until November 30,2024.The median PFS was(14.45±2.52)months in the observation group and(11.14±2.31)months in the control group.The 1-year survival rate was 78.26％(36/46)in the observation group and 52.00％(26/50)in the control group.The differences in median PFS and 1-year survival rate between the two groups were statistically significant(P＜0.05).The incidence of grade Ⅰ-Ⅱ leukopenia in the observation group was higher than that in the control group,and the incidences of grade Ⅲ-Ⅳ nausea and vomiting,and alopecia in the obser-vation group were higher than those in the control group,with statistically significant differences(P＜0.05).Conclusion TAS-102 combined with bevacizumab for the third-line and above treatment of ad-vanced metastatic colon cancer can improve the efficacy and prolong the PFS of patients.Although the in-cidence of toxic and side effects in some patients is increased,there is no grade Ⅲ and above liver and kid-ney damage.关键词
转移性结肠癌/贝伐珠单抗/曲氟尿苷替匹嘧啶片/疗效Key words
Metastatic colon cancer/Bevacizumab/Trifluridine and tipiracil tablets/Efficacy引用本文复制引用
刘朝辉,李程,辛祎..曲氟尿苷替匹嘧啶片联合贝伐珠单抗治疗晚期转移性结肠癌的临床研究[J].中国肛肠病杂志,2025,45(5):17-20,4.基金项目
开封市科技发展计划项目(230316) （230316）
